Sol-Gel Technologies (NASDAQ:SLGL) Issues Earnings Results

Sol-Gel Technologies (NASDAQ:SLGL) posted its quarterly earnings results on Thursday. The company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($0.04), Zacks reports. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.30 million. Sol-Gel Technologies had a negative net margin of 14.25% and a negative return on equity of 11.80%.

Sol-Gel Technologies Trading Down 0.8%

Shares of SLGL stock opened at $35.75 on Friday. Sol-Gel Technologies has a twelve month low of $4.02 and a twelve month high of $52.26. The stock has a market cap of $99.60 million, a P/E ratio of -29.07 and a beta of 1.35. The stock has a 50 day moving average of $34.18 and a 200 day moving average of $19.56.

Wall Street Analyst Weigh In

SLGL has been the subject of a number of research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sol-Gel Technologies in a report on Wednesday, October 8th. Zacks Research raised shares of Sol-Gel Technologies to a “hold” rating in a research report on Tuesday, October 28th. HC Wainwright lifted their price objective on shares of Sol-Gel Technologies from $6.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Finally, Wall Street Zen downgraded shares of Sol-Gel Technologies from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $50.00.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.